RELAPSE MULTIPLE MYELOMA
Clinical trials for RELAPSE MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSE MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSE MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
Disease control OngoingThis phase 1 trial tests a new approach for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The study uses two different CAR T cell therapies—one targeting a protein called GPRC5D and another targeting BCMA—given together …
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for myeloma: adaptive trial tests smarter drug combos
Disease control OngoingThis phase II trial is testing new therapies, including the drug teclistamab, for people with multiple myeloma that has relapsed or not responded to treatment. About 300 participants will be enrolled in an adaptive platform design that allows adding new treatment arms over time. …
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Multiple Myeloma Research Consortium • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo shows promise for myeloma patients who failed earlier therapy
Disease control OngoingThis study tests a combination of four drugs (daratumumab, clarithromycin, pomalidomide, and dexamethasone) in people with multiple myeloma whose cancer returned or didn't respond after previous treatment with daratumumab. The goal is to see if this combo can shrink tumors more e…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC